Optimizing the NIR Fluence Threshold for Nanobubble Generation by Controlled Synthesis of 10 - 40 nm Hollow Gold Nanoshells.

The laser fluence to trigger nanobubbles around hollow gold nanoshells (HGN) with near infrared light was examined through systematic modification of HGN size, localized surface plasmon resonance (LSPR), HGN concentration, and surface coverage. Improved temperature control during silver template synthesis provided monodisperse, silver templates as small as 9 nm. 10 nm HGN with < 2 nm shell thickness were prepared from these templates with a range of surface plasmon resonances from 600 - 900 nm.

Retraction of "Tunable Plasmonic Nanoprobes for Theranostics of Prostate Cancer".

[This retracts the article on p. 3 in vol. 1, PMID: 21547151.

Methods for Generation and Detection of Nonstationary Vapor Nanobubbles Around Plasmonic Nanoparticles.

Laser pulse-induced vapor nanobubbles are nonstationary nanoevents that offer a broad range of applications, especially in the biomedical field. Plasmonic (usually gold) nanoparticles have the highest energy efficacy of the generation of vapor nanobubbles and such nanobubbles were historically named as plasmonic nanobubbles. Below we review methods (protocols) for generating and detecting plasmonic nanobubbles in liquids.

All-in-one processing of heterogeneous human cell grafts for gene and cell therapy.

Current cell processing technologies for gene and cell therapies are often slow, expensive, labor intensive and are compromised by high cell losses and poor selectivity thus limiting the efficacy and availability of clinical cell therapies. We employ cell-specific on-demand mechanical intracellular impact from laser pulse-activated plasmonic nanobubbles (PNB) to process heterogeneous human cell grafts ex vivo with dual simultaneous functionality, the high cell type specificity, efficacy and processing rate for transfection of target CD3+ cells and elimination of subsets of unwanted CD25+ cells. The developed bulk flow PNB system selectively processed human cells at a rate of up to 100 million cell/minute, providing simultaneous transfection of CD3+ cells with the therapeutic gene (FKBP12(V36)-p30Caspase9) with the efficacy of 77% and viability 95% (versus 12 and 60%, respectively, for standard electroporation) and elimination of CD25+ cells with 99% efficacy.